{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:06:21Z","timestamp":1776459981394,"version":"3.51.2"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.therap.2026.03.003","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:43:05Z","timestamp":1774928585000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lercanidipine-associated peripheral oedema after pristinamycin introduction: A pharmacokinetic interaction hypothesis"],"prefix":"10.1016","author":[{"given":"H\u00e9l\u00e8ne","family":"Geniaux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9mie","family":"Bordes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4344-0359","authenticated-orcid":false,"given":"Marie-Laure","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2026.03.003_bib0075","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/HJH.0b013e3283472643","article-title":"Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate\u00a0\u2013\u00a0a meta-analysis of randomized trials","volume":"29","author":"Makani","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.therap.2026.03.003_bib0080","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1111\/bcp.14752","article-title":"Drug-induced peripheral oedema: an aetiology-based review","volume":"87","author":"Largeau","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2026.03.003_bib0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2515\/therapie\/2013016","article-title":"Updating the French method for the causality assessment of adverse drug reactions","volume":"68","author":"Arimone","year":"2013","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2026.03.003_bib0090","unstructured":"Base de donn\u00e9es publique des m\u00e9dicaments. 2026. https:\/\/base-donnees-publique.medicaments.gouv.fr\/index.php. [Accessed 27 March 2026]."},{"key":"10.1016\/j.therap.2026.03.003_bib0095","series-title":"Stockley's drug interactions: a source book of interactions, their mechanisms, clinical importance and management","author":"Baxter","year":"2013"},{"key":"10.1016\/j.therap.2026.03.003_bib0100","series-title":"Thesaurus des interactions m\u00e9dicamenteuses","year":"2020"},{"key":"10.1016\/j.therap.2026.03.003_bib0105","unstructured":"DDI Predictor. 2025. https:\/\/www.ddi-predictor.org\/predictor\/ddi. [Accessed 27 March 2026]."},{"key":"10.1016\/j.therap.2026.03.003_bib0110","series-title":"Martindale: the complete drug reference","author":"Buckingham","year":"2020"},{"key":"10.1016\/j.therap.2026.03.003_bib0115","unstructured":"Drugs.com. Pyostacine (International). 2025. https:\/\/www.drugs.com\/international\/pyostacine.html. [Accessed 27 March 2026]."},{"key":"10.1016\/j.therap.2026.03.003_bib0120","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2515\/therapie\/2014033","article-title":"Interaction pristinamycine\/antivitamine K\u00a0: analyse de la base fran\u00e7aise de pharmacovigilance","volume":"69","author":"Guiboux","year":"2014","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2026.03.003_bib0125","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/00003088-200443040-00003","article-title":"Clinical pharmacokinetics of quinupristin\/dalfopristin","volume":"43","author":"Bearden","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"suppl_1","key":"10.1016\/j.therap.2026.03.003_bib0130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/44.suppl_1.37","article-title":"Safety and tolerability of quinupristin\/dalfopristin: administration guidelines","volume":"44","author":"Rubinstein","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.therap.2026.03.003_bib0135","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0922-4106(95)90193-0","article-title":"Interaction of pristinamycin IA with P-glycoprotein in human intestinal epithelial cells","volume":"288","author":"Phung-Ba","year":"1995","journal-title":"Eur J Pharmacol Mol Pharmacol"},{"key":"10.1016\/j.therap.2026.03.003_bib0140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.18773\/austprescr.2014.050","article-title":"P-glycoprotein and its role in drug\u2013drug interactions","volume":"37","author":"Finch","year":"2014","journal-title":"Aust Prescr"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T20:34:07Z","timestamp":1776458047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595726000508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":14,"alternative-id":["S0040595726000508"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2026.03.003","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lercanidipine-associated peripheral oedema after pristinamycin introduction: A pharmacokinetic interaction hypothesis","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2026.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}